# The Extracellular Matrix in Liver Regeneration: Biological and Therapeutic Insights

**Authors:** Haodong Ma, Wenyue Wu, Wen Zhang, Hong Li, Ziyan Pan, Caihong Wang, Ruoyu Gao, Qiushuang Ji, Zhi Chen, Hong You, Wei Chen

PMC · DOI: 10.3390/bioengineering13030335 · Bioengineering · 2026-03-13

## TL;DR

The liver's extracellular matrix plays a key role in regeneration by controlling cell signals and tissue repair, offering new therapeutic strategies for liver disease.

## Contribution

The paper reveals the ECM as an active, dynamic system that regulates liver regeneration through mechano-biochemical signaling.

## Key findings

- The liver ECM functions as a mechano-biochemical circuit that regulates cell proliferation and tissue restructuring.
- ECM signals influence pathways like Hippo-YAP/TAZ and Wnt/β-catenin to control regeneration outcomes.
- Modulating ECM composition and mechanics offers therapeutic potential for liver repair and disease treatment.

## Abstract

The liver possesses a remarkable regenerative capacity following injury, a process fundamentally orchestrated by the dynamic extracellular matrix (ECM). Far beyond a passive scaffold, the liver matrisome functions as an integrative mechano-biochemical circuit. It comprises a core structural network together with regulatory non-core components that collectively establish a dynamic niche. This niche stores and releases mitogenic cues, transmits mechanical forces, and coordinates multicellular crosstalk. Through receptors like integrins and mechanosensitive channels, ECM-derived signals converge on key pathways, including Hippo-YAP/TAZ and Wnt/β-catenin, to drive hepatocyte proliferation and tissue restructuring. The balance between matrix stabilization and remodeling dictates the outcome, guiding physiological regeneration versus fibrotic progression. Consequently, the ECM emerges as a central therapeutic target and a blueprint for engineering strategies aimed at restoring liver function. Strategies to recalibrate its composition, mechanics, and remodeling, from pharmacological inhibitors to bioengineered decellularized ECM scaffolds, hold significant potential for steering liver repair and combating chronic liver disease.

## Linked entities

- **Proteins:** ITGB1 (integrin subunit beta 1), YAP1 (Yes1 associated transcriptional regulator), TAFAZZIN (tafazzin, phospholipid-lysophospholipid transacylase), ctnnb1.S (catenin beta 1 S homeolog)
- **Diseases:** liver disease (MONDO:0005154)

## Full-text entities

- **Genes:** CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, TAFAZZIN (tafazzin, phospholipid-lysophospholipid transacylase) [NCBI Gene 6901] {aka BTHS, CMD3A, EFE, EFE2, G4.5, LVNCX}
- **Diseases:** liver disease (MESH:D008107)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13024264/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13024264/full.md

## References

119 references — full list in the complete paper: https://tomesphere.com/paper/PMC13024264/full.md

---
Source: https://tomesphere.com/paper/PMC13024264